One major focus is the changing state of T cells exposed to cancer for prolonged periods. Rather than treating exhaustion as a single dysfunctional condition, researchers increasingly view it as a spectrum of differentiation states governed by distinct transcriptional and metabolic programs. Some exhausted T cells retain the capacity to self-renew or respond to checkpoint blockade, while others are more terminally impaired. This distinction could help clinicians choose treatments that restore function without pushing cells beyond recovery. Other work shows that tumor-primed memory T cells can display features of senescence and heightened sensitivity to type I interferons, signaling molecules that are essential for antiviral defense but can worsen immune dysfunction during cancer vaccination if activated at the wrong time. The implication is that vaccine priming, booster schedules and checkpoint inhibition may need to be synchronized with the changing biology of each immune-cell population rather than delivered according to fixed schedules.

The tumor’s immune geography may be just as important as the immune cells themselves. Tissue-resident memory CD4-positive T cells in non-small-cell lung cancer express elevated levels of immune checkpoint molecules and produce XCL1, a chemokine that attracts dendritic cells. Although dendritic cells can help initiate T-cell responses by presenting tumor antigens, the surrounding regulatory environment may blunt the effectiveness of checkpoint blockade. This finding offers a possible explanation for why patients with apparently similar tumors can respond very differently to the same therapy. Beyond the tumor, cancer can remodel the spleen, a major site of immune-cell development and coordination. Changes in splenic architecture and function may alter systemic immunity before treatment even begins, potentially influencing whether circulating T cells, antigen-presenting cells and myeloid populations are prepared to support tumor rejection. The emerging view is that immunotherapy must account for immune organs throughout the body, not only the tumor mass visible on a scan.

Myeloid cells provide another layer of control. Macrophages can engulf malignant cells, present antigens and release inflammatory signals, but tumors frequently reprogram them into tumor-associated macrophages that support growth, blood-vessel formation and immune suppression. Studies in the special issue examine macrophage extracellular traps, web-like structures released by activated macrophages that may promote tumor progression or alter immune-cell behavior. In liver cancer, fibrates—drugs traditionally used to regulate lipid metabolism—enhanced responses to immune checkpoint blockade by inhibiting PLTP-driven infiltration of M2-like macrophages, a population commonly associated with tissue repair and immune suppression. Another study identified LMO7 as a molecular brake on macrophage phagocytosis of cancer cells. Removing or overcoming this brake could strengthen innate immunity, the rapid, antigen-independent arm of defense that operates before highly specific T-cell responses develop. These findings suggest that successful immunotherapy may require simultaneous control of both adaptive lymphocytes and the myeloid cells that determine whether lymphocytes can function inside tumors.

Metabolism and the tumor microenvironment are also being treated as active therapeutic targets rather than passive background conditions. Tumors often accumulate lactate as a consequence of high rates of glycolysis, even when oxygen is available. Lactate can alter immune-cell signaling and drive protein lactylation, a chemical modification that influences gene expression and may stabilize immunosuppressive cell states. By connecting metabolic waste to epigenetic regulation, this research identifies a route through which tumor metabolism can produce lasting changes in immune behavior. The local microbiome adds another variable. A nanozyme designed to target the intratumoral bacterium Peptostreptococcus anaerobius was reported to reverse resistance to ferroptosis, an iron-dependent form of regulated cell death. Reconfiguring microbial niches could therefore make cancer cells more vulnerable to treatment. Meanwhile, blocking secretion of exosomes containing the protein Fgl2, combined with anti-PD-L1 therapy, prevented activation of myeloid-derived suppressor cells. These studies portray tumors as ecosystems in which metabolites, bacteria and extracellular vesicles continuously transmit instructions to immune cells.

Bioengineering is providing tools to rewrite those instructions with greater precision. Manganese–DNA complex extracellular vesicles were designed to reprogram dendritic cells inside pancreatic tumors, potentially improving antigen presentation and the subsequent activation of tumor-specific T cells. Yet another vesicle platform containing ACLY was used to model how engineered particles can induce immunosuppressive macrophage states in liver cancer, illustrating that delivery systems are not biologically neutral: their cargo, surface properties and tissue distribution can determine whether they stimulate or suppress immunity. At the tumor–immune interface, the experimental agent DSP216 simultaneously targets HLA-G and CD47, two signals associated with immune evasion. HLA-G can inhibit lymphocyte activity, while CD47 functions as a “don’t eat me” signal that protects cancer cells from phagocytosis. Blocking both pathways could expose tumors to complementary attacks from adaptive and innate immune cells. Antibody–drug conjugates add another layer of engineering by linking tumor-targeting antibodies to cytotoxic payloads through specialized chemical linkers. Their effectiveness depends on selecting the right antigen, controlling drug release and balancing tumor killing against damage to healthy tissues.

The same design principles are reshaping adoptive cell therapy, in which immune cells are collected, modified or expanded outside the body and then returned to the patient. Chimeric antigen receptor T cells have produced dramatic responses in some blood cancers, but solid tumors present formidable obstacles, including poor cell trafficking, physical barriers, antigen heterogeneity and an immunosuppressive microenvironment. Several studies address these problems by adding new sensing and survival functions to CAR-T cells. An anti-PD-1 nanobody was incorporated into mesothelin-targeting CAR-T cells developed for mesothelioma, allowing the cells to counter checkpoint signaling locally rather than relying entirely on systemic antibody treatment. Humanized, charge-optimized CAR-T cells directed against CSPG4 showed improved activity against head and neck squamous-cell carcinoma, while a CCR4/CD7 bispecific CAR-T design expanded recognition logic by requiring or exploiting two antigenic targets. Researchers are also examining G protein-coupled receptors as a broader control and targeting space for CAR-T engineering. These receptors influence migration, activation and responses to chemokines, making them potential handles for steering therapeutic cells through hostile tumor tissue.

Adoptive therapy is not limited to CAR-T cells. Natural killer cells can recognize stressed or transformed cells without the same antigen-specific receptor requirements as T cells, and their biology offers a complementary route to cancer treatment. In one strategy, NK cells were conjugated to adipose-derived mesenchymal stem cells engineered to express interleukin-15. The stem-cell component was intended to improve tumor localization, while IL-15 supports NK-cell proliferation and cytotoxic activity. Patient-derived tumor-infiltrating lymphocytes are also being advanced as individualized products; work in acral melanoma demonstrates how immune cells extracted from a patient’s own tumor can be expanded and reinfused. Bispecific T-cell engagers, which physically bring T cells into contact with cancer cells, are being humanized for use against tumors in the central nervous system and elsewhere. Nanoparticles may further improve these approaches by controlling the delivery and biodistribution of immunomodulators or chemotherapy, reducing exposure in healthy tissues while concentrating supportive signals near therapeutic cells.

Because tumors deploy several escape mechanisms at once, the collection argues that combinations must be designed mechanistically rather than assembled by trial and error. Reviews of unsuccessful combination trials emphasize the value of biomarker-guided sequencing, dose optimization and adaptive designs that allow researchers to learn during a study and modify treatment arms as evidence accumulates. Artificial intelligence and large language models are being considered for biomarker discovery, patient stratification and treatment optimization, although their usefulness will depend on high-quality clinical and molecular data. Combination studies include antibody–drug conjugates carrying anti-tubulin or topoisomerase I inhibitor payloads alongside radiotherapy, using controlled tumor damage to enhance immune priming. Chemo-immunotherapy is being explored in immune-enriched pancreatic cancer, while an rWTC-MBTA vaccine paired with anti-PD-1 treatment has been evaluated in central nervous system and peripheral B-cell lymphoma. Other approaches combine CDK4/6 inhibitors with checkpoint therapy to regulate tumor-associated macrophages through MIF signaling, or stimulate β2-adrenergic receptors to increase cytotoxic T-cell activity through CXCL10 in p53-deficient head and neck tumors.

Taken together, the studies outline a transition from broad immune stimulation to calibrated immune engineering. Durable responses may require a sequence of interventions: first altering metabolism or suppressive myeloid cells, then improving antigen presentation, guiding immune-cell entry and finally sustaining T-cell or NK-cell activity after tumors begin to shrink. Such strategies could also make treatment more dependent on measurable biological features, including checkpoint expression, macrophage states, chemokine signals, microbial composition, metabolic signatures and the presence of expandable tumor-reactive lymphocytes. The field still faces major challenges, including toxicity, manufacturing complexity, tumor evolution and the difficulty of predicting immune behavior across patients. But the combined research points toward an increasingly programmable form of oncology in which therapies are engineered to disable specific escape mechanisms while preserving the timing and location of immune activation. The goal is not merely to provoke an immune response, but to make that response persistent, adaptable and difficult for cancer to evade.

Tumor neoantigens arise from genetic mutations unique to cancer cells and do not exist in normal tissues, making them ideal “flags” for the immune system to differentiate malignant cells from healthy ones. These mutated peptides, when presented on the surface of tumor cells via the major histocompatibility complex (MHC), can activate T cells, pivotal players in adaptive immunity that orchestrate targeted destruction of cancerous cells. However, one of the biggest challenges in the development of cancer vaccines lies in discerning which neoantigens will effectively stimulate a T cell response potent enough to eradicate tumors.

The research team, led by Dr. Karen Taraszka Hastings, Chair of Dermatology at the University of Arizona College of Medicine – Phoenix, developed a sophisticated mouse model mimicking human cSCC. This model revealed an unexpectedly high burden of tumor mutations, mirroring genetic alterations seen in both human patients and laboratory mice. Within this plethora of mutations, two neoantigens stood out—derived from mutations in the Picalm and Kars proteins—that independently provoked robust anti-tumor T cell responses, arresting tumor progression in vivo.

Detailed immunological analyses illuminated fascinating mechanistic differences between these two neoantigens. The mutated Picalm peptide displayed a striking capacity to bind the MHC molecules, a prerequisite for T cell recognition, whereas its normal, non-mutated counterpart failed to achieve such MHC presentation. This discrepancy elucidates why mutated Picalm effectively alerts the immune system while the wild-type version does not. In contrast, the mutated and normal versions of the Kars peptide showed similar binding affinities to MHC, suggesting that differential MHC presentation alone could not explain the enhanced immune response against mutated Kars.

To resolve this conundrum, the scientists turned to cutting-edge AI-powered, three-dimensional structural modeling of the neoantigen-MHC complexes. This computational approach revealed subtle but critical conformational changes on the surface of the mutated Kars peptide exposed to the T cell receptor. These structural modifications alter the chemical landscape perceived by T cells, triggering a targeted immune response capable of tumor control. This finding underscores the importance of considering the three-dimensional architecture—not just peptide sequence or MHC binding affinity—when predicting which neoantigens will be immunogenic.

Building on these insights, the researchers conducted comprehensive analyses across an array of known neoantigens individually assessed for tumor control efficacy in experimental settings. They found a consistent pattern: effective tumor-rejecting neoantigens exhibited increased surface exposure of mutated residues accessible to T cell receptors, reaffirming the pivotal role of structural presentation in anti-cancer immunity.

Dr. Hastings emphasizes the transformative potential of integrating AI-driven structural modeling into neoantigen discovery pipelines. “Our approach offers a refined lens to select the most promising neoantigens for inclusion in personalized cancer vaccines, especially for highly mutated tumors such as those arising in skin cancers and melanoma,” she explained. By precisely predicting T cell-activating neoantigens, this methodology could drastically enhance vaccine specificity and effectiveness, streamlining therapeutic development pathways.

Moreover, the team’s interdisciplinary collaboration—spanning computational biology, immunology, and dermatology—exemplifies the convergence of data science and clinical research in modern medicine. David Ebert, Chief AI and Data Science Officer at the University of Arizona, hailed the study as a prime example of AI’s impact in revolutionizing cancer therapeutics. The integration of machine learning algorithms with molecular biology has paved the way for novel diagnostic and treatment modalities poised to revolutionize patient care.

Looking ahead, the researchers plan to validate their findings using human tumor samples, aiming to translate this innovative neoantigen identification strategy into personalized vaccine design for patients. Successful application of this framework could markedly improve outcomes in cSCC and other mutationally complex cancers by harnessing the body’s own immune arsenal with unprecedented precision.

This pioneering work was supported by prominent funding sources, including the National Cancer Institute and the National Institute of General Medical Sciences, ensuring the robust interdisciplinary efforts that bridged computational modeling with immunotherapy research. The team also involved MD/PhD trainees and scientists from multiple institutions, exemplifying the collaborative nature of cutting-edge cancer research.

By unveiling how subtle structural alterations in tumor proteins dictate immune recognition, this study advances our fundamental understanding of tumor immunogenicity and paves the way for personalized cancer vaccines designed with unparalleled accuracy. As artificial intelligence continues to permeate biomedical sciences, approaches like this will likely become indispensable tools in the fight against cancer, promising new hope for patients worldwide.

Subject of Research: Animals

Article Title: Structural changes from wild-type define tumor-rejecting neoantigens

News Publication Date: 22-Oct-2025

Web References: https://jitc.bmj.com/content/13/10/e013148

Keywords: Health and medicine; Diseases and disorders